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Pain: Nocistatin spells relief
William J. Martin, Annika B. Malmberg and Allan I. Basbaum
Tissue or nerve injury can dramatically alter the
transmission of sensory stimuli by spinal cord neurons,
so that a light touch produces pain. The discovery that
peptide products of prepronociceptin processing either
facilitate or inhibit these mechanisms suggests novel
approaches to treating these conditions.
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Although morphine and other opioids are very effective in
the treatment of pain produced by tissue injury, such as
postoperative pain, the ‘neuropathic’ pain associated with
nerve injury is often unresponsive to opioids [1]. There is
now considerable evidence that neuropathic pain results
from a prolonged central sensitization or hyperexcitability
of dorsal horn neurons in the spinal cord, which enhances
the transmission of ‘pain’ messages. When this occurs,
patients and animals experience allodynia, in which a
normally non-noxious stimulus such as a light touch
evokes pain, and/or hyperalgesia, in which normally
painful (noxious) stimuli produce an exaggerated pain
response. Studies of the neurochemical basis of this
central sensitization have implicated a variety of media-
tors, including glutamate acting at N-methyl-D-aspartic
acid (NMDA) receptors. In many respects, the develop-
ment of these long-lasting changes in the spinal cord are
comparable to the mechanisms that govern synaptic plas-
ticity in the cortex and hippocampus.
More recently, attention has focused on the contribution
of specific peptide neurotransmitters to the development
of allodynia and hyperalgesia. Nociceptin, a 17 amino-acid
peptide that is an endogenous ligand for the opioid-like
receptor ORL1, was found to increase pain responses in
mice [2]. Specifically, when nociceptin was injected at low
doses intrathecally, that is into the cerebrospinal fluid of
the spinal cord, it produced allodynia and hyperalgesia.
Because nociceptin, like opioids, increases a K+ conduc-
tance and decreases a Ca2+ conductance, this result was
surprising, particularly so because ORL1 resembles the µ,
δ and κ opioid receptors, which bind analgesia-producing
opioids such as morphine. In fact, under some conditions,
nociceptin is analgesic. Apparently, the route of adminis-
tration, dose and state of the animal are critical variables
that determine whether nociceptin inhibits or facilitates
the transmission of pain messages [3]. The pronociceptive
— pain-enhancing — nature of nociceptin was especially
provocative because it raised the possibility that this mol-
ecule comes into play in the clinical setting of allodynia,
and indeed these initial studies have led to some exciting
new findings that we describe below.
Okuda-Asitaka et al. [4] have recently found that the noci-
ceptin precursor, prepronociceptin, is also processed to
produce peptides that counteract the effects of nociceptin.
Their studies identified several new peptide products of
prepronociceptin. The most interesting of these, bPNP-3
or nocistatin, was found to block the allodynia and hyperal-
gesia produced by intrathecal injection of low doses of
nociceptin. Nocistatin also reversed the allodynia produced
by prostaglandin E2 (PGE2), but it did not affect nocicep-
tive thresholds when injected by itself. These results indi-
cate that, although nocistatin may regulate allodynic states
of differing etiologies, it is not an analgesic; unlike mor-
phine, nocistatin does not raise pain thresholds (Figure 1).
In addition to identifying another peptide, bPNP-4, that
countered the hyperalgesic action of nociceptin but not its
allodynia-producing properties, the authors identified the
requisite sequence for the anti-allodynic action of nocis-
tatin. They also showed that injection of an anti-nocistatin
antibody further reduced the dose of nociceptin required
to produce allodynia. Taken together, these results
Figure 1
The relationship between stimulus intensity and pain, showing how
injury and different drugs shift the stimulus–response functions.
(a) Under normal conditions, a noxious stimulus is required for pain.
(b) Injury or intrathecal injection of nociceptin shifts the response curve
to the left, so that innocuous stimuli now produce pain (allodynia) and
noxious stimuli produce exaggerated pain responses (hyperalgesia).
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strongly suggest that the function of endogenous nocistatin
is to normalize nociceptive (pain) thresholds (Figure 1). 
Two fundamental questions emerge from these initial
observations. First, what is the mechanism of nocistatin-
induced reversal of allodynia? And second, does nocistatin
reverse tissue or nerve injury-induced allodynia? Because
nociceptin, which lowers the pain threshold, and nocistatin,
which normalizes the pain threshold, are synthesized in the
same neurons, the key to understanding the allodynic/anti-
allodynic effects of these peptides is to identify their target
receptors and to determine their cellular distribution in the
dorsal horn (Figure 2). Nociceptin [5] and nocistatin [4] are
both expressed in lamina II of the dorsal horn. The ORL1
receptor is also expressed in this region [6], but because it
is also found in dorsal root ganglion cells, it is likely that
nociceptin acts, at least in part, upon the presynaptic termi-
nals of primary afferents [2] (Figure 2). 
Importantly, Okuda-Asitaka et al. [4] demonstrated that
nocistatin binds a receptor that is distinct from that of
nociceptin, but the identity of the nocistatin receptor is
not yet established. Without this information one cannot
determine whether the ORL1 and nocistatin receptors are
expressed in the same or different neurons. The cellular
location of the ORL1 and the nocistatin receptors is of
particular interest, because we recently demonstrated that
mice with a deletion of the gene that encodes the gamma
isoform of protein kinase C (PKCγ) do not develop nerve-
injury allodynia [7]. Because the neurons that express
PKCγ are restricted to a subpopulation of interneurons in
the inner part of lamina II of the dorsal horn (Figure 2), it
is possible that nociceptin induces allodynia via circuits
that involve the PKCγ-containing interneurons.
What about the possible contribution of these molecules in
clinically relevant conditions of allodynia and hyperalgesia?
To address these questions, it will be important to study
the action of nociceptin and nocistatin in the setting of
injury, when pain thresholds are pathophysiologically
lowered. Does the level of nociceptin increase when there
is tissue or nerve injury-induced allodynia? Do the con-
centrations correspond to those that induce allodynia and
anti-allodynia when injected intrathecally? Can nocistatin
block these changes? Okuda-Asitaka et al. [4] established
that nocistatin is present in vivo, but they only measured
levels in normal animals. Some indication that significant
changes occur comes from the studies of Andoh et al. [8],
who found that persistent inflammation induced an
increase in the level of prepronociceptin mRNA in the
dorsal root ganglion — the cell bodies of primary afferent
fibers that transmit pain messages. Because prepronoci-
ceptin mRNA is not detectable in the dorsal root ganglion
of normal animals, this finding indicates that this gene is
subject to regulation after injury. Interestingly, the peak
of the inflammation-induced increase in prepronociceptin
mRNA occurred before the onset of allodynia; if differen-
tial processing occurs such that the main prepronoci-
ceptin-derived peptide produced during the early stages
of inflammation is nocistatin, it may contribute to the
absence of allodynia at this time.
The fact that nociceptin produces antinociception at
higher doses considerably complicates the analysis of its
contribution to pain in the setting of injury. For example,
nociceptin has been shown to inhibit the phenomenon of
‘wind-up’, a gradual increase in the firing of dorsal horn
neurons that results from repetitive activation of small
diameter, unmyelinated C-fibers [9]. This implies that
nociceptin can decrease the noxious-stimulus-evoked
hyperexcitability of dorsal horn neurons. Nociceptin also
reduces noxious-stimulus-induced neurogenic inflamma-
tion [10], and it reduces pain behavior in the setting of
injury [11]. From these observations, it is possible that
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Figure 2
The major elements of the superficial dorsal
horn through which noxious stimuli evoke
pain. Nociceptive primary afferent A-δ and
C-fibers (red) are activated by noxious stimuli;
this information is transmitted to interneurons
(purple/green) and projection neurons (blue)
of the dorsal horn. The interneurons are
concentrated in lamina II and the projection
neurons in laminae I and V. As nociceptin is
found in lamina II (yellow), its precursor
prepronociceptin is probably synthesized by
interneurons that act postsynaptically on
projection neurons and presynaptically on the
terminals of primary afferents, both of which
express the ORL1. The PKCγ interneurons
(purple) that have been implicated in injury-
induced allodynia are exclusively found in the















higher concentrations of nociceptin are generated under
conditions of injury, resulting in anti-nociceptive rather
than pro-nociceptive effects. But will we find, once the
nocistatin receptor has been identified, that many of the
reported effects of higher doses of nociceptin are, in fact,
mediated via the nocistatin receptor? Until antagonists for
both receptors are developed, it will be difficult to resolve
these issues.
A better understanding of the molecules that underlie
injury-induced allodynia and hyperalgesia is critical to the
development of new therapies for the treatment of pain. At
present, morphine is the drug of choice for severe pain, but
there are many problems associated with its use. Tolerance
to the analgesic action of morphine develops with long-
term use and morphine produces significant deleterious
side effects. Furthermore, as illustrated in Figure 1, mor-
phine produces analgesia by shifting the ‘normal pain’
stimulus-response curve to the right — this may disrupt
the important protective signal that acute pain provides. 
We recently demonstrated that mice with a deletion of the
gene that encodes the primary afferent tachykinins —
including substance P and neurokinin A — experience the
low end of ‘normal’ pain, but are much less responsive to
intense pain stimuli [12]. These animals still developed
allodynia in the setting of tissue and nerve injury,
however, so tachykinin antagonists may not, by them-
selves, be useful clinically. The ideal treatment would
counteract the leftward shift of the curve that occurs in the
setting of injury, without altering normal pain (Figure 1).
That such therapies can be developed now appears possi-
ble. For example, although the PKCγ mutant mice did not
develop allodynia after injury, their acute pain thresholds
were unchanged. Similarly, although nocistatin blocked
nociceptin and PGE2-evoked allodynia, it did not alter
thresholds when administered alone. If it turns out that
nocistatin can block the allodynia that occurs with injury,
then these new observations may herald the development
of a class of centrally-acting molecules that are selective
for injury-associated pain conditions. There are many
more questions than answers, but nocistatin may indeed
prove to be a new way to spell relief.
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